Capra CLO Founders
SlowingNew York, NYBiotechnology, Pharmaceuticals, HealthcareLast fund filed August 2015
1 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Capra CLO Founders Fund, L.P. | August 2015 | $250M | $120M | 24 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
1 partner is named across this firm’s filings, 1 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| James Healy | Slowing | Biotech & pharma, Digital health | 12 | 1 |
Classified sectors of Capra CLO Founders’s own portfolio companies, based on 12 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Capra CLO Founders’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Sofinnova Venture Partners | 12 | ArriVent Biopharma, Ascendis Pharma A/S, Atsena Therapeutics, BioAge Labs, Bolt Biotherapeutics, CEBIX, DXTERITY DIAGNOSTICS, HYPERION THERAPEUTICS, Iterum Therapeutics Bermuda, Iterum Therapeutics, Seaport Therapeutics, Sorbent Therapeutics |
| Caduceus Capital | 2 | ArriVent Biopharma, Ascendis Pharma A/S |
| Orbimed Asia Partners | 2 | ArriVent Biopharma, Ascendis Pharma A/S |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| Orbimed Genesis | 2 | ArriVent Biopharma, Ascendis Pharma A/S |
| Orbimed Global Healthcare | 2 | ArriVent Biopharma, Ascendis Pharma A/S |
| Orbimed Israel Partners | 2 | ArriVent Biopharma, Ascendis Pharma A/S |
| Orbimed New Horizons | 2 | ArriVent Biopharma, Ascendis Pharma A/S |
| Orbimed Partners | 2 | ArriVent Biopharma, Ascendis Pharma A/S |
| Orbimed Private Investments | 2 | ArriVent Biopharma, Ascendis Pharma A/S |
| Vivo Capital | 2 | Ascendis Pharma A/S, Bolt Biotherapeutics |
| ARCH Venture Partners | 1 | Seaport Therapeutics |
| Longitude Capital | 1 | BioAge Labs |
| New Leaf | 1 | Iterum Therapeutics Bermuda |
| Pivotal bioVenture Partners | 1 | Bolt Biotherapeutics |
| Vivo Innovation | 1 | Bolt Biotherapeutics |
A shared board seat: a company where filings name a Capra CLO Founders partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.